Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and Masimo's claims are rejected in court. Apple and medical equipment maker ...

In its first earnings report since the departure of longtime CEO Joe Kiani, Masimo said Tuesday it is focused on reducing spending to drive long-term growth. The company continues to evaluate ...

IRVINE, Calif. (AP) — IRVINE, Calif. (AP) — Masimo Corp. (MASI) on Tuesday reported third-quarter earnings of $9.8 million. On a per-share basis, the Irvine, California-based company said it ...

Piper Sandler raised the firm’s price target on Masimo (MASI) to $180 from $165 and keeps an Overweight rating on the shares. The firm notes the company announced Q3 revenue of $505M finished ...

Ladies and gentlemen, good afternoon, and welcome to Masimo's Third Quarter 2024 Earnings Conference Call. The company's press release is available at www.masimo.com. At this time, all lines have ...

Apple and Masimo are back in a California court this week for a bench trial that will see Masimo arguing that Apple illegally poached its employees and stole trade secrets when developing the ...

Masimo MASI is set to give its latest quarterly earnings report on Tuesday, 2024-11-05. Here's what investors need to know before the announcement. Analysts estimate that Masimo will report an ...

In this article, we are going to take a look at where Masimo Corporation (NASDAQ:MASI) stands against other most promising medical stocks. The healthcare sector depends on medical technology ...

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO ...

The FDA has only approved one medical wearable that provides continuous oxygen saturation (SpO2) and pulse rate tracking: the Masimo W1 Medical watch. “If you really want a wearable that’s ...

IRVINE, California - Masimo (NASDAQ:MASI) Corporation (NASDAQ:MASI) reported third-quarter earnings that beat analyst expectations, but its shares tumbled 7.5% as fourth-quarter revenue guidance ...